News | September 18, 2013
Oxford Immunotec Wins Place Again on The Sunday Times Hiscox Tech Track 100
Oxford, UK and Marlborough, MA; 18 September 2013 – Oxford Immunotec has been awarded a place on the prestigious Sunday Times Tech Track 100 league table for the second year running. Ranking Britain’s 100 private technology companies with the fastest-growing sales over the last three years, Tech Track 100 is compiled by Fast Track, the Oxford company that researches Britain’s top-performing private companies.
Commenting on the company’s inclusion in the Tech Track 100 list, Dr. Peter Wrighton-Smith, Oxford Immunotec’s Chief Executive Officer, said, “We are delighted to have the success of the company recognised again. Oxford Immunotec’s revenues have grown strongly, driven by the sales of our diagnostic test for Tuberculosis to an increasing list of countries.” He added, “we are proud to be building a successful company while making a significant difference to the global fight against Tuberculosis, which remains a major public health threat worldwide.”
The Sunday Times Tech Track 100 league table was published in the Sunday Times on 15th September 2013.
We are a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Our proprietary T-SPOT technology platform allows us to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human body’s immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, cancers and autoimmune diseases. We are headquartered near Oxford, UK and in Marlborough, MA.
About T-SPOT®.TB test
The initial product we have developed using our T-SPOT technology platform is our T-SPOT.TB test, which is used to test for latent Tuberculosis infection. Our T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where we have received pre-market approval from the Food and Drug Administration, in Europe, where we have obtained a CE mark, as well as Japan and China. Our T-SPOT.TB test has been included in TB screening guidelines in 17 countries, including the United States, several European countries and Japan.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
